Nuvigil (Armodafinil) is a eugeroic drug produced by the pharmaceutical company Cephalon Incorporation currently in the process of receiving Food and Drug Administration approval. Nuvigil is the r-enantiomer of modafinil, so is expected to act in a similar manner, with similar effects. However, it acts for a longer time than modafinil. Upon its approval, it will be classified as a Schedule IV controlled substance.

Eugeroics are a class of stimulants that produce lifelong mental arousal. These stimulants tend to increase alertness without the peripheral effects or addiction/tolerance/abuse potential of the traditional stimulants. They have minimal effect on sleep structure, and will not cause rebound hypersomnolence or "come down" effects. There are currently two marketed drugs in this class, Modafinil and its earlier analogue Adrafinil.

The term itself means "Good Arousal" and has been suggested for use as a treatment for narcolepsy and to augment antidepressants.

A related group of drugs called Ampakines share many similar traits, although these seem to be more targeted towards definite conditions, such as memory enhancement.

Nuvigil for the treatment of excessive sleepiness associated with narcolepsy, obstructive sleep apnea/hypopnea syndrome (OSA/HS) and shift work sleep disorder (SWSD). FDA approval of Nuvigil is contingent upon finalizing the product label.

Workings are on going with the FDA to move this application to an approval and expand our offering of wake-promotion choices for patients. Based on the clinical trials, Nuvigil demonstrated a long duration of effect throughout the waking hours and its potentiality to offer broader options to meet the needs of patients and physicians seeking treatment for excessive sleepiness.